PRIP's Second Call Builds a Milestone-Based Path from Lab Research to MarketScience & Technology

GS Paper 3 · 29 August 2026

PRIP's Second Call Builds a Milestone-Based Path from Lab Research to Market

The Department of Pharmaceuticals opened a second call under the ₹5,000 crore Promotion of Research and Innovation in Pharma and MedTech scheme. Early-stage projects from startups and MSMEs can move technologies at Technology Readiness Levels 1, 2 or 3 to a stage not beyond TRL 5, with assistance up to ₹5 crore per project. Later-stage applicants at TRL 4, 5 or 6 can seek support up to ₹100 crore, capped at 35% of approved project cost, with the balance co-funded by the applicant. The two-track design recognises that discovery, validation and scale-up face different risks. Public funding should therefore be tied to technically meaningful milestones, independent review, patient safety, intellectual-property strategy and credible routes to manufacturing or adoption. Technology-readiness labels help organise a pipeline but do not prove clinical value or affordability. Success must include useful products, regulatory evidence, domestic capability and public-health access, not merely applications approved or funds disbursed.

Why UPSC cares

For GS Paper 3, connect pharmaceutical innovation with R&D finance, startups, MSMEs, technology readiness, commercialisation and self-reliance. For GS Paper 2, relate innovation support to health-system need, safety and affordability.

How to study this story

The laboratory-to-market gap arises because promising science can fail during validation, scale-up, regulation, manufacturing or adoption. A two-track funding design can match support to these different risks. Early projects need proof of concept, reproducibility and a credible next experiment; later projects require robust prototypes, quality systems, clinical or performance evidence, manufacturability and market or health-system demand. Technology Readiness Levels provide a shared vocabulary, but progress should be verified through discipline-specific milestones rather than self-declared labels. Co-funding at later stages can test commercial commitment, although it may disadvantage socially valuable projects with uncertain markets. Selection should therefore consider unmet health need, affordability and domestic strategic value alongside private return. Independent expert review, conflict-of-interest controls, milestone payments and termination rules protect public money. Intellectual-property terms should encourage collaboration without preventing access. Post-award reporting should track patents and prototypes but also regulatory approval, production capability, procurement and patient benefit. PRIP succeeds when public risk capital produces safe, useful and accessible innovation while strengthening Indian research and manufacturing networks.

The larger paper context

For GS Paper 3, distinguish capacity from headline scale. Subscriber totals, export authorisations, IIP growth, reactor capacity and technology-readiness levels become meaningful only when measurement, risk controls, implementation capability and final outcomes are examined together.

Probable question

Public R&D support must bridge the laboratory-to-market gap without confusing technology readiness with public-health value. Discuss with reference to the PRIP scheme.

Quick practice check

  1. Q1

    What distinguishes the later-stage PRIP funding track?

    1. It supports only TRL 1 ideas
    2. It can provide up to ₹100 crore subject to a 35% project-cost cap and co-funding
    3. It requires no milestones
    4. It excludes startups and MSMEs
    Show answer

    Correct answer: It can provide up to ₹100 crore subject to a 35% project-cost cap and co-funding

    Later-stage projects at TRL 4-6 may receive larger assistance, capped at 35% of approved cost with applicant co-funding.

  2. Q2

    Why can Technology Readiness Level not be the sole success measure?

    1. TRL already proves affordability
    2. TRL organises technical maturity but does not prove safety, clinical value or access
    3. TRL measures only company revenue
    4. TRL removes the need for regulation
    Show answer

    Correct answer: TRL organises technical maturity but does not prove safety, clinical value or access

    Technical maturity is important, but public-health value also needs independent safety, performance, affordability and adoption evidence.

Related previous-year questions

  • UPSC GS-3: Indigenisation of technology and developing new technology
Read the primary source ↗